UNASSIGNED: We conducted a prospective observational cohort study across 30 sites in 21 Thai provinces to analyze the use of \"Ganja Oil,\" a cannabis extract in 10% coconut oil, prescribed for symptoms like pain, anorexia, and insomnia across a diverse patient group, including cancer and migraines. Quality of life was assessed using the Edmonton Symptom Assessment Scale (ESAS) and EQ-5D-5L at baseline, 1, 2, and 3 months. The study included a predefined subgroup analysis to compare the effects on cancer versus non-cancer patients. Data management was facilitated through Research Electronic Data Capture (REDCap), with statistical analysis performed using Stata/MP.
UNASSIGNED: Among 21,284 participants, the mean age was 54.10 ± 15.32 years, with 52.49% being male. The baseline EQ-5D-5L index was 0.85 ± 0.24. Significant differences in EQ-5D-5L indices were seen between cancer patients (0.79 ± 0.32) and non-cancer patients (0.85 ± 0.23; p < 0.001). ESAS scores also differed significantly between these groups for all symptoms, except anxiety. The most frequent prescription of Ganja Oil was oral administration at bedtime (88.26%), with the predominant dosage being three drops daily, approximately 0.204 mg of tetrahydrocannabinol in total. Posttreatment, significant improvements were noted: the EQ-5D-5L index increased by 0.11 points (95% CI: 0.11, 0.11; p < 0.001) overall, 0.13 points (95% CI: 0.12, 0.14; p < 0.001) for cancer patients, and 0.11 points (95% CI: 0.10, 0.11; p < 0.001) for non-cancer patients. ESAS pain scores improved by -2.66 points (95% CI: -2.71, -2.61; p < 0.001) overall, -2.01 points (95% CI: -2.16, -1.87; p < 0.001) for cancer patients, and -2.75 points (95% CI: -2.80, -2.70; p < 0.001) for non-cancer patients, with similar significant improvements in other symptoms.
UNASSIGNED: Our study indicates potential benefits of Ganja Oil for improving quality of life among Thai patients, as a complementary treatment. These findings must be viewed in light of the study\'s design limitations. Further controlled studies are essential to ascertain its efficacy and inform dosing guidelines.
■我们在泰国21个省的30个地点进行了一项前瞻性观察性队列研究,以分析“GanjaOil”的使用情况,“10%椰子油中的大麻提取物,为疼痛等症状开处方,厌食症,以及不同患者群体的失眠,包括癌症和偏头痛.在基线时使用埃德蒙顿症状评估量表(ESAS)和EQ-5D-5L评估生活质量,1、2和3个月。该研究包括预定义的亚组分析,以比较对癌症与非癌症患者的影响。通过研究电子数据采集(REDCap)促进了数据管理,使用Stata/MP进行统计分析。
■在21,284名参与者中,平均年龄54.10±15.32岁,52.49%是男性。基线EQ-5D-5L指数为0.85±0.24。在癌症患者(0.79±0.32)和非癌症患者(0.85±0.23;p<0.001)之间,EQ-5D-5L指数存在显着差异。所有症状的ESAS评分在这些组间也有显著差异,除了焦虑.GanjaOil的最常见处方是在睡前口服(88.26%),主要剂量是每天三滴,总计约0.204mg四氢大麻酚。后处理,注意到显著改善:EQ-5D-5L指数总体上增加了0.11点(95%CI:0.11,0.11;p<0.001),癌症患者为0.13分(95%CI:0.12,0.14;p<0.001),非癌症患者为0.11分(95%CI:0.10,0.11;p<0.001)。ESAS疼痛评分总体改善-2.66分(95%CI:-2.71,-2.61;p<0.001),癌症患者的-2.01分(95%CI:-2.16,-1.87;p<0.001),和-2.75分(95%CI:-2.80,-2.70;p<0.001),其他症状也有类似的显著改善。
■我们的研究表明,GanjaOil对改善泰国患者的生活质量具有潜在的益处。作为补充治疗。这些发现必须根据研究的设计限制来看待。进一步的对照研究对于确定其功效和告知给药指南至关重要。